|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD19-targeted chimeric antigen receptor (CAR) T-cells (CAR19s) show remarkable efficacy in the treatment of relapsed/refractory acute lymphocytic leukemia and Non-Hodgkin's lymphoma.
|
31242389 |
2019 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this article is to provide consensus opinion from experts in the fields of hematopoietic cell transplantation, cellular immunotherapy, and lymphoma regarding key clinical questions pertinent to the use of CD19 CAR T cell products for the treatment of NHL.
|
31446199 |
2019 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical success of autologous CD19-directed chimeric antigen receptor T cells (CAR Ts) in acute lymphoblastic leukemia and non-Hodgkin lymphoma suggests that CAR Ts may be a promising therapy for hematological malignancies, including multiple myeloma.
|
31005597 |
2019 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chimeric antigen receptor (CAR) T cells spark hope for patients with CD19+ B cell neoplasia, including relapsed or refractory (r/r) acute lymphoblastic leukaemia (ALL) or r/r non-Hodgkin's lymphoma (NHL).
|
31110096 |
2019 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chimeric antigen receptor T cells (CAR-T) with anti-CD19 have shown great promise in the treatment of relapsed and refractory non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL).
|
31428935 |
2019 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD19-targeting chimeric antigen receptor (CAR)-T cell therapy has shown great efficacy in patients with relapsed/refractory non-Hodgkin lymphoma (NHL) but has been associated with serious adverse effects, such as cytokine release syndrome (CRS).
|
30769193 |
2019 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
Two anti-CD19 CAR T cell products were approved by the FDA for the treatment of patients with relapsed or refractory aggressive B cell NHL.
|
30919158 |
2019 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
This cohort includes 24 patients treated with CD19-directed CAR T cells for non-Hodgkin lymphoma (n = 23) and acute lymphoblastic leukemia (n = 1), and 1 patient treated with α-fetoprotein-directed CAR T cells for hepatocellular carcinoma (n = 1).
|
30808634 |
2019 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
AFM11 is a tetravalent, bispecific CD19/CD3 immunoengager based on Affimed's ROCK platform, currently being investigated in phase I clinical trials for non-Hodgkin lymphoma and acute lymphoblastic leukemia.
|
31090657 |
2019 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, a reduced dose of a PD‑1 inhibitor combined with CD19 CAR‑T cells appears to be a promising treatment option for relapsed/refractory B‑NHL exhibiting high PD‑1 expression by T cells.
|
30942469 |
2019 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
Strategies to augment the cytokine response to lymphodepletion could be tested in future studies of CD19 CAR T-cell immunotherapy for aggressive B-cell NHL.
|
30782611 |
2019 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interaction kinetics with transcriptomic and secretory responses of CD19-CAR natural killer-cell therapy in CD20 resistant non-hodgkin lymphoma.
|
31772298 |
2019 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chimeric antigen receptor modified T (CAR-T) cell therapy against the CD19 antigen has revolutionized the therapeutic landscape for patients with relapsed, refractory B cell non-Hodgkin lymphoma (NHL).
|
30652353 |
2019 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
The astonishing clinical success of CD19 chimeric antigen receptor (CAR) T-cell therapy has led to the approval of two second generation chimeric antigen receptors (CARs) for acute lymphoblastic leukemia (ALL) andnon-Hodgkin lymphoma (NHL).
|
30394400 |
2018 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
CARs targeting CD19, a cell surface molecule found in most leukemias and lymphomas, have yielded high remission rates in patients with chemorefractory, relapsed disease, including acute lymphoblastic leukemia, chronic lymphocytic leukemia, and non-Hodgkin lymphoma.
|
29032264 |
2018 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
A single-cell analysis of the preinfusion CD19 CAR product from patients with NHL demonstrated that CAR products contain polyfunctional T-cell subsets capable of deploying multiple immune programs represented by cytokines and chemokines, including interferon-γ, IL-17A, IL-8, and macrophage inflammatory protein 1α.
|
29895668 |
2018 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
Current, up-to-date published studies on anti-CD19 CAR therapy for acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and non-Hodgkin lymphoma (NHL) with observed side effects are discussed and an outlook on 58 ongoing trials is given.
|
27479233 |
2016 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, our CD19/CD3 BsAb is a useful tool that could be a suitable candidate for treatment of NHL.
|
22421972 |
2012 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we evaluated the antitumor effects of the microtubule destabilizing agent monomethyl auristatin E (MMAE) conjugated to the humanized anti-CD19 antibody hBU12 via a protease-sensitive valine-citrulline (vc) dipeptide linker. hBU12-vcMMAE induced potent tumor cell killing against rituximab-sensitive and -resistant NHL cell lines.
|
19147785 |
2009 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results demonstrate that patients with CD19(+) NHL would be suitable candidates for this form of therapy in the setting of a phase I clinical trial.
|
15842655 |
2005 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
Biomarker
|
disease |
BEFREE |
Synergistic antitumor effect of bispecific CD19 x CD3 and CD19 x CD16 diabodies in a preclinical model of non-Hodgkin's lymphoma.
|
12077238 |
2002 |
|
Lymphoma, Non-Hodgkin
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A case of chemotherapy-resistant non-Hodgkin's lymphoma simultaneously expressing T cell (CD7)-, B cell (CD19)- and myeloid (CD13, CD33)-associated surface antigens is presented.
|
2540603 |
1989 |